^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DM919

    i
    Other names: DM919
    Associations

    News

    Trials
    Company:
    D2M biotherap
    Drug class:
    NK cell stimulant, MICA inhibitor, MICB inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, D2M Biotherapeutics Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Mar 2026
    Enrollment closed • Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab) • DM919
    almost2years
    A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=160, Recruiting, D2M Biotherapeutics Inc. | Active, not recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • DM919
    almost2years
    A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, D2M Biotherapeutics Inc.
    New P1 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • DM919
    over3years
    DM919, a potent anti-MICA/B antibody, reinforces NKG2D-MICA/B axis and promotes anti-tumor activities in preclinical models (SITC 2022)
    Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
    Preclinical • IO biomarker
    |
    CD8 (cluster of differentiation 8) • MICA (MHC Class I Polypeptide-Related Sequence A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
    |
    DM919